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Abstract 
Modafinil is a wakefulness-promoting drug increasingly used off-label for cognitive 
neuroenhancement in healthy persons, despite conflicting empirical support. The 
present study aimed to investigate the effects of 200mg of modafinil on behavioural 
(reaction time and accuracy) and neural (N1 ERP component) measures of 
attentional alerting and orienting in healthy humans using a Revised Attentional 
Network Task paradigm. Healthy non-sleep deprived males (N=18) completed the 
task at baseline and 3 hours post-ingestion (single dose 200mg modafinil or placebo) 
in this randomised, double-blind, counterbalanced, within-subjects study. They self-
reported mood (Profile of Mood States – Short Form), fatigue (Karolinska Sleepiness 
Scale) and Subjective Performance and Drug Effects (Visual Analogue Scales). The 
results indicated that modafinil prevented feelings of fatigue experienced in the 
placebo condition, enhancing both tonic and phasic alerting attention, as indicated by 
increased N1 amplitude and reduced RT for no cue and central cue trials. Some 
enhancement of the orienting network (RT and N1 to spatial cues) was observed, but 
it was of no greater in magnitude than the alerting effects. Therefore, the orienting 
effect was likely a consequence of the interdependent nature of the networks. These 
results are a preliminary indication of the positive effect of modafinil on alerting 
components of attention in healthy persons. Future research should aim to further 
substantiate these findings, as the current study was slightly underpowered. Studies 
should also investigate tentative evidence discovered for enhancement of the 
executive attentional network, indicated by improved inhibition of incongruent 
flankers. 
 
  
  
2 
Modafinil (2-[(diphenylmethyl)sulfinyl]acetamide) is a wakefulness 
promoting agent (eugeroic) that is increasingly used among healthy people for 
cognitive neuroenhancement despite unclear empirical support. Modafinil increases 
dopamine, norepinephrine and orexin levels within the cerebral cortex (Minzenberg 
& Carter, 2008). As these neurotransmitters are strongly related to each of the 
alerting, orienting and executive attentional networks, effects of modafinil on these 
systems are expected (Petersen & Posner, 2012). The neurochemical processes are 
also responsible for the decreased drowsiness in sleep-deprived individuals 
(Minzenberg & Carter, 2008). Consequentially, modafinil is listed as a Schedule IV 
prescription drug to treat somnolence experienced by narcolepsy patients, shift 
workers and sleep-apnoea sufferers. Amongst these sleep-deprived individuals, 
Modafinil has been demonstrated to improve cognitive functions (including 
attention) with similar efficacy to amphetamine drugs, and with reduced occurrence 
of side effects and addiction (Minzenberg & Carter, 2008). Recent meta-analyses of 
studies in healthy non sleep-deprived samples report conflicting findings as to 
whether these neuro-enhancing effects are observed (Battleday & Brem, 2015; 
Repantis, Schlattmann, Laisney, & Heuser, 2010). Despite this inconclusive 
evidence, off-label use of modafinil continues in a range of healthy persons including 
business people, pilots and students (Repantis et al., 2010). It is important to 
investigate whether modafinil can be neuro-enhancing for healthy non-sleep 
deprived persons, as use in this population has monetary, legal and moral 
consequences.  
Neurochemical Effects of Modafinil  
Modafinil is a psychostimulant that targets the brains sleep and arousal 
systems. Modafinil causes an increase in catecholamines by directly inhibiting the 
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uptake transporters for dopamine and noradrenaline (Qu, Huang, Xu, Matsumoto, & 
Urade, 2008). This results in the rise of cerebral serotonin, orexin and histamine, as 
well as a concurrent decrease of GABA (Qu et al., 2008). Modafinil’s influence on 
catecholamines and their interaction with the orexins axis likely underlies its 
promotion of arousal, wakefulness and potentially, attention (Minzenberg & Carter, 
2008).  
The Attentional Networks 
Attention is the function of distributing cognitive resources to stimuli in the 
environment (Coull, 1998). Petersen and Posner (2012) identified the alerting, 
orienting and executive systems as three distinct, yet interactive, networks of 
attention. The role of the alerting network is to prepare the brain to be vigilant in 
identifying and responding to stimuli. This requires arousal, which relies on 
norepinephrine. Given that modafinil stimulates norepinephrine production in both 
the hypothalamus and the prefrontal cortex, it would be expected to enhance 
performance on alerting tasks (de Saint Hilaire, Orosco, Rouch, Blanc, & Nicolaidis, 
2001).  
To study alerting, researchers can present participants with a warning cue 
prior to a target. This elicits phasic alertness, the component of alerting that is 
responsible for modulating preparedness (Petersen & Posner, 2012). The participant 
accumulates a heightened sense of expectation for the onset of the target and 
therefore, responds faster. Alternatively, researchers can investigate tonic alertness, 
which refers to resting-state arousal (Petersen & Posner, 2012). Tonic alertness can 
be measured using tasks that measure sustained attention, the ability to maintain 
vigilance over a prolonged period.  
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The orienting network is responsible for deploying and shifting attention 
towards stimuli within the sensory field (Petersen & Posner, 2012). Attention 
shifting (Vossel, Geng, & Fink, 2014). When important and unexpected stimuli 
appear in the sensory field, the temporoparietal junction influences the ventral frontal 
cortex to re-orient attention towards it (Vossel et al., 2014). For example, the ventral 
system is enacted when a target appears in an unexpected spatial location, such as 
after an invalid cue. The dorsal orienting system, in contrast, is responsible for the 
deployment of attention based on expectations (Vossel et al., 2014). This system has 
two key nodes; the intraparietal sulcus and the frontal eye fields. These areas include 
retinotopic organisation of maps for the spatial environment which provide a top-
down influence on the orienting of attention (Silver & Kastner, 2009). The dorsal 
network activates to orient attention spatially, such as after a cue that informs the 
viewer of where an upcoming target will appear in the sensory field. 
The executive network of attention facilitates selective attention and the 
suppression of distractors (Petersen & Posner, 2012). These functions are top-down, 
rely on the dopamine neurotransmitter, and stem from the anterior cingulate cortex 
(ACC) and prefrontal brain areas (Posner & Petersen, 1990; Posner, Rueda, & 
Kanske, 2007). As a single dose of modafinil increases cortical dopamine and 
activity in the ACC node of the LFPCN, it may enhance executive attention 
(Esposito et al., 2013). 
The Acute Effects of Modafinil on Attention  
Studies investigating the attentional effects of modafinil have conflicting 
findings. Repantis et al. (2010) found that healthy non sleep-deprived individuals had 
a moderate, significant improvement in their performance on attentional tasks after a 
single dose of modafinil compared with baseline (d>0.50). The tasks assessed 
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components of attention that rely on the alerting network (Detection of Repeated 
Numbers [DRN], Serial Reaction Time [SRT], Rapid Visual Information Processing 
[RVIP], Mackworth Clock (MC) and other simple RT tasks). Executive attention was 
not analysed as relevant studies rarely collected baseline data. There was also a lack 
of research for orienting attention.  
Battleday and Brem (2015) conducted a more recent review of the literature, 
separating studies based on attention type. They observed conflicting results and 
concluded that the majority had found no enhancement of ‘alertness’ or ‘sustained 
attention’ following administration of modafinil. The inconsistency in findings may 
be attributed to methodological differences, wherein those studies reporting null 
effects generally lacked sufficient sensitivity to detect the effects of modafinil. They 
were potentially underpowered due to ceiling effects, with many of the tasks lacking 
the cognitive demand for participants to demonstrate improvement. Past studies were 
also often limited by small samples and failure to adequately address confounding 
variables (such as IQ, caffeine and nicotine usage). 
Modafinil and the Alerting Network  
As tonic and phasic alertness share a reliance on norepinephrine, 
enhancement of either is potential evidence of enhancement for the other. However, 
the studies that have investigated the effects of modafinil on alertness in healthy 
samples have had mixed findings (see Table 1). This is likely due to methodological 
issues, particularly ceiling effects. Only one study investigating the attentional 
effects of modafinil in a healthy, non sleep deprived sample has included a task 
designed to elicit both phasic and tonic alertness (Liepert, Allstadt-Schmitz, & 
Weiller, 2004). These researchers used a reaction time (RT) task with trials that 
included either no warning signal (measuring tonic alertness) or an alerting cue (an 
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auditory beep, measuring phasic alertness) that was indicative of an upcoming target 
(an unspecified go-signal). For all trials, the participants pressed a right-button at 
target onset. Participants completed this task after receiving placebo or modafinil 
(Liepert et al., 2004). As expected, RT to the target was significantly faster for trials 
with a warning cue compared to those with no cue. There was no difference in RT 
between the modafinil and placebo groups for trials preceded by no cue (g=0.14) or a 
warning cue (g=0.08) (Liepert et al., 2004). They concluded that modafinil does not 
enhance tonic or phasic alertness. However, this finding may have been due to a lack 
of power, as ten participants was unlikely to be sufficient to detect the effect of 
modafinil in a healthy sample on such a simple task (Liepert et al., 2004). A task 
with higher cognitive load might allow any improvement to be more observable.   
 Baranski, Pigeau, Dinich, and Jacobs (2004) used a more difficult task to 
assess the influence of modafinil on the alerting network. They compared the effects 
of placebo with modafinil in participants who completed a cognitive battery three 
times per session (baseline, 90-minutes and 180-minutes post-ingestion). The 
cognitive battery included the DRN to measure sustained attention; participants 
viewed changing three-digit numbers on a screen and responded to rare repeated 
numbers, using a button press. Participants also completed a 3-minute SRT task to 
measure tonic alertness. When a probe letter appeared at the top of the screen the 
participant had to move a cursor and click on its matching counterpart amongst 
flankers at the bottom of the screen. Participants were significantly more accurate on 
the DRN for modafinil compared with placebo at both post-ingestion testing points. 
They were also significantly faster on the SRT at 3 hours post-ingestion for the 
modafinil condition compared with placebo. Furthermore, they reported significantly 
lower fatigue for the modafinil condition (Baranksi et al., 2004). These findings are 
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indicative of modafinil enhancing the alerting network. Participants were asked to 
abstain from caffeine and nicotine for 48 hours before the study. These substances 
are known to enhance attention and those dependent on them may merely be restored 
to baseline after ingesting modafinil, rather than experiencing any further 
enhancement. However, the within-subjects design likely prevented this skewing the 
results (Baranksi et al., 2004).  
Theunissen et al. (2009) compared the cognitive effects of modafinil with 
other stimulants and placebo. Participants completed the MC task, which measures 
sustained attention, as part of a larger cognitive battery. This task involved the 
presentation of 60 grey dots in a circular formation on a screen. The dots illuminated 
sequentially and the participant was asked to press a button when a dot was skipped. 
As the skips occured rarely, fewer missed targets and faster RT indicated greater 
sustained attention. Participants were significantly faster in the modafinil condition 
relative to placebo (g=2.65), with no significant change in accuracy (Theunissen et 
al., 2009). This indicates that modafinil enhances alertness. The researchers 
acknowledged that this finding may generalise poorly as data was missing for three 
participants, due to computer error.  
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Table 1 
Alerting Effects of Modafinil in Healthy Non-Sleep Deprived Participants 
Author SS  Design Dose  Measures  Significance (p) and Effect Size (d or g) 
Liepert and 
Weiller (2004) 
10M PC, DB; 
R; WS 
200mg Alertness 
(Tonic,  Phasic) 
Simple RT task  
No significant difference if performance for modafinil compared with placebo 
for NC trials (g=0.14) or WC trials (g=0.08). No p value provided.  
Baranski et al. 
(2004) 
18M PC; DB; 
R; WS 
4mg/kg Sustained 
attention; DRN 
Tonic Alertness; 
SRT  
Significantly improved accuracy on DRN for modafinil compared with placebo 
at both post-ingestion testing points (1.5 hours p<0.003, 3 hours p<0.05).  
Significantly faster RT on the 3 hour post-ingestion SRT for the modafinil 
condition compared with placebo. 
Effect sizes not calculated as standard error/deviation was not provided. 
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Table 1. Continued. 
Alerting Effects of Modafinil in Healthy Non-Sleep Deprived Participants 
Authors SS  Design Dose  Measures  Significance (p) and Effect Size (d or g) 
Theunissen, 
Elvira Jde, van 
den Bergh, and 
Ramaekers 
(2009) 
16 (5M) PC; DB; 
R; WS 
200mg Sustained 
attention: 
Mackworth 
Clock Task 
Large and significant reduction of RT for MC task for modafinil compared 
with placebo (p=0.001, g=2.65).  
No significant change in accuracy (p=N/S). 
 
Randall, 
Shneerson, and 
File (2005) 
89 (47M, 
42F) 
PC; DB; 
R; BS 
100/ 
200mg 
Sustained 
attention: RVIP; 
a) RT 
b) missed 
targets 
Participants were faster in the 200mg modafinil condition compared with 
placebo, regardless of IQ. However, the magnitude of this effect was much 
greater for the low IQ group (g=0.43) compared with the high IQ group 
(g=2.51, d=2.54). Furthermore, the number of missed targets was lower in the 
modafinil condition across IQ groups, p<0.05, without notable changes in 
accuracy.  
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Table 1. Continued. 
Alerting Effects of Modafinil in Healthy Non-Sleep Deprived Participants 
Authors SS  Design Dose  Measures  Significance (p) and Effect Size (d or g) 
Turner et al. 
(2003) 
60M PC; DB; 
R; BS 
100/ 
200mg 
Sustained 
attention: RVIP 
(RT) 
No significant difference between the three drug conditions, p=0.915. All 
effect sizes for differences were less than small (g<0.15) 
Winder-Rhodes 
et al. (2010) 
12M PC; DB; 
R; WS 
300mg Sustained 
attention: RVIP 
a) accuracy 
b) response bias 
a) No significant difference in accuracy between groups, p=0.981, g=0.01 
b) No significant difference in response bias between groups, p=0.317, g=0.00 
 
Note: All measures were conducted as a part of larger cognitive batteries. Design abbreviations: M=male; F=female; PC=placebo-controlled; DB=double-
blind; R=randomised; WS=within-subjects; BS=between-subjects. Task abbreviations: DRN=Detection of Repeated Numbers; SRT=Serial Reaction 
Time; RVIP=Rapid Visual Information Processing [RVIP]. Effect sizes not calculated/reported if data absent.   
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Randall, Shneerson, and File (2005) investigated the effects of modafinil 
compared with placebo in healthy university students who completed a cognitive 
battery, including the RVIP, 2-3 hours post-ingestion. The RVIP requires 
participants to view serially presented digits on a screen and respond with a button 
press when they detect an infrequent 3-digit sequence. Faster RT and fewer missed 
targets indicate greater sustained attention. The participants were split according to 
whether they had lower (≤110) or higher (≥111) IQ (measured with the National 
Adult Reading Test-II; Nelson and Willison, 1991). Participants were faster in a 
200mg modafinil condition compared with placebo. The magnitude of this effect was 
greater for the low (g=0.43) compared with high IQ group (g=2.51). This study 
indicates that alertness is enhanced by modafinil, but that this effect may be less 
observable in simple tasks, particularly if participants have higher IQs.  
 Turner et al. (2003) and Winder-Rhodes et al. (2010) also used the RVIP to 
observe the effects of modafinil in healthy samples. Turner et al. (2003) observed 
non-significant, negligible differences between modafinil and placebo on RVIP 
performance (all gs<0.15). Similarly, Winder-Rhodes et al. (2010) found no 
difference in RVIP performance across drug conditions. The mean IQ for both 
samples was high, and the RVIP was a simple task, which together may have masked 
any cognitive enhancing effects of modafinil for both studies. Furthermore, Winder-
Rhodes et al.’s (2010) participants abstained from caffeine and nicotine pre-session. 
Any who were dependent users would likely have experienced withdrawal effects, 
with the modafinil merely returning them back to their baseline cognitive 
performance. 
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The Effects of Modafinil on the Orienting Network 
Within both sleep deprived and healthy populations there is a lack of 
research investigating whether modafinil influences orienting attention. Esposito et 
al. (2013) used fMRI to observe the effects of modafinil (100mg) on resting-state 
brain activity at baseline and three hours post-ingestion in 26 males. For the 
modafinil condition, there was a significant increase in activation for both the 
Dorsal Attention Network (DAN) and the ACC node of the left Frontal Parietal 
Control Network (LFPCN). The increase in DAN activity indicates that modafinil 
may enhance performance on orienting tasks by influencing top-down deployment 
of attention (Esposito et al., 2013). Furthermore, the orienting network can be 
influenced by the alerting network. For example, if a participant is primed with an 
alerting cue such as an auditory beep, their RT to a subsequent orienting cue is 
reduced (Callejas, Lupianez, Funes, & Tudela, 2005). Therefore, it may be expected 
to improve orienting as a consequence (Baranski et al., 2004; Theunissen et al., 
2009, Randall et al., 2005). Alternatively, modafinil might be expected to enhance 
orienting attention due to its effects on the executive network. 
The Effects of Modafinil on the Executive Network  
Focusing on a particular aspect of a stimuli (selective attention) and 
inhibiting irrelevant stimuli (inhibition) are core functions of the executive network 
of attention that rely on dopamine. Given the capacity of modafinil to increase 
dopamine production, enhancing effects on tasks involving the executive system are 
expected. As with the alerting network, some studies have reported null effects, 
which can again be attributed to methodological issues. For example, studies 
investigating the effects of modafinil on executive attention in healthy samples often 
apply clinical measures used to identify defects, which results in ceiling effects and 
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makes any enhancement induced by modafinil unobservable (Battleday & Brem, 
2013). 
 However, there has been a more adequate response to these methodological 
issues in literature for executive attention compared with alerting attention. Studies 
including cognitively challenging tasks demonstrate that modafinil may enhance 
executive functioning (Battleday & Brem, 2015). In one such study, Geng et al. 
(2013) requested that participants guess which side of the screen an upcoming 
stimulus would appear in for each of 400 trials. For the first half of the task, the 
stimulus was more likely to occur on one side 70% of the time. For the second half it 
occurred equally on both sides. Geng et al. (2013) found that modafinil improved 
probability learning (an executive function). Furthermore, RT to the target was 
decreased when the target occurred where the participant predicted, indicating a 
corollary enhancement of spatial orienting. This is consistent with the understanding 
that top-down projections from the frontal and parietal lobes influence excitatory and 
inhibitory biases in the visual field (Hopfinger & West, 2006). These findings 
support the expectation for modafinil to enhance executive attention, as well as being 
suggestive of orienting enhancement.  
The Revised Attentional Network Task  
The Revised Attentional Network Task (R-ANT) (Neuhaus et al., 2010) is 
designed to test the alerting, orienting and executive networks of attention, as well as 
their interactions. Efficiency of each network is examined by changes in RT to a 
target resulting from particular cue types. Targets may be preceded by no cue (the 
continuation of the fixation point), a central cue (an asterisk appearing over the 
fixation point, or two asterisks presented above and below the screen) or a spatial cue 
(an asterisk that appears above or below the fixation point). When there is no cue, the 
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participant is in a state of relative readiness, as they are aware that the target will 
appear at some stage (tonic alertness). Central cues are more informative than no 
cue, acting as a warning signal and eliciting a state of phasic alertness and 
preparedness for the upcoming target. Alerting is indexed by the difference between 
RT to the target for trials with no cue compared to those with central cues. Spatial 
cues always validly predict the location of the subsequent target. This activates the 
orienting network and makes spatial cues more informative than central cues. 
Therefore, orienting is indexed by the difference between RT after central cues 
compared with spatial cues. The subsequent target is a central arrow in a horizontal 
row of five, which may appear above or below the fixation point. The participant’s 
task is to decide whether the target is pointing left or right and use a button press to 
indicate their choice. The target stimuli are presented with flankers such as congruent 
or incongruent arrows. This elicits executive attention as responding to the 
incongruent trials requires the participant to inhibit the influence of the flanking 
stimuli. Executive attention effects can be calculated by comparing RT to the target 
after incongruent trials with congruent or neutral trials.  
Neuhaus et al. (2010) found that RT decreased with cue informativity. 
Participants were slowest for no cue, faster for central cues and fastest for spatial 
cues, with differences between all types being significant. The differences in cue 
types is indicative of their ability to engage the alerting and orienting attentional 
networks. Target type elicited the executive network as expected, as RT was 
significantly faster to congruent compared with incongruent targets. 
Electrophysiological Correlates of Attention 
Event-related potentials (ERPs) are fluctuations in electrical activity in the 
brain that are time-locked to a stimulus or cognitive event (Luck, 1995). ERPs can be 
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applied to directly measure neural activity that is linked with particular attentional 
mechanisms (Luck, 1995). The occipital N1 ERP is a negative component which 
peaks maximally at around 150ms post-stimulus. It is thought to index voluntary 
orienting to stimuli in the sensory field, as well as the processing of this stimuli 
(Näätänen & Michie, 1979; Vogel & Luck, 2000). Neuhaus et al. (2010) found that 
the N1 ERP component was modulated by both alerting and orienting cues. They 
reported that target locked N1 amplitude was lowest for no cue, higher for alerting 
cues and highest for spatial cues. This suggests that orienting towards, and 
processing of, a target increases with cue informativity. If modafinil enhances 
alerting or orienting aspects attention, this pattern of amplitude may be expected to 
be greater in a modafinil condition in comparison with a placebo condition.  
Rationale, Aim and Hypotheses 
Previous studies investigating the effects of modafinil in healthy persons have 
tended to incorporate attentional measures into large cognitive batteries rather than 
looking at specific mechanisms of attention. It appears that the measures of attention 
employed have sometimes been simple and under-sensitive or confounded by other 
variables (Liepert & Weiller 2004; Turner, 2003; Winder-Rhodes et al., 2010). When 
these limitations are better addressed, studies indicate that modafinil improves 
sustained attention, suggesting an influence on the alerting network of attention 
(Baranski et al., 2004; Theunissen et al., 2009, Randall et al., 2005). 
The current study aimed to address these methodological concerns by 
employing the ANT-R to measure specific attentional mechanisms which correspond 
to three separable attentional networks. Additionally, regular nicotine smokers were 
excluded from the study and participants were asked to consume equal levels of 
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caffeine on both drug and placebo sessions in a within-subjects design. Intake of both 
and a measure of IQ were all collected, to identify any influence of these factors.  
There has been very little research which has specifically examined separate 
aspects of the attentional networks, particularly orienting and the phasic component 
of alerting. Furthermore, there has been no previous research which has investigated 
the ERPs underlying the attentional effects of Modafinil in a healthy sample. Thus, 
the present study aimed to investigate the effects of 200mg of modafinil on 
behavioural (RT and accuracy) and neural (N1 ERP component) measures of 
attentional alerting and orienting in healthy humans using an ANT-R paradigm. 
Consistent with previous research, it was hypothesised that RT would be 
slowest for targets preceded by no cue, faster for central cues and fastest for orienting 
cues. The influence of modafinil on norepinephrine and sustained attention tasks 
suggests that modafinil enhances alerting attention (Baranski et al., 2004; de Saint 
Hilaire et al., 2001; Theunissen et al., 2009, Randall et al., 2005). If modafinil does 
enhance phasic alertness, a significantly greater reduction in RT between baseline 
and post-ingestion for targets preceded by central cues, for the modafinil relative to 
the placebo condition is expected. 
No previous research has investigated the effects of modafinil on the 
orienting network. It was alternatively hypothesised that if modafinil directly 
enhances the orienting network, there would be a significantly greater reduction in 
RT for targets between the central and spatial cues from baseline to post-ingestion for 
the modafinil condition relative to the placebo condition. 
Consistent with previous research, it was hypothesised that overall, N1 
amplitude would be lower for targets preceded by no cue, greater (i.e., more 
negative) for alerting cues and greatest for orienting cues. If modafinil has a direct 
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effect on alerting, it was hypothesised that there would be a greater significant 
increase in N1 amplitude for central cues for the modafinil relative to placebo 
condition. If modafinil has a direct effect on orienting, it was hypothesised that there 
would be a greater increase in N1 amplitude between central and spatial cues for the 
modafinil relative to placebo condition. 
Method 
Participants  
An a priori power calculation indicated that 20 participants were required to 
detect moderate sized effects (f=.25) with power of 0.8. The current study recruited 
19 participants and the results for one were excluded from analysis, because he did 
not complete the second session. The final sample consisted of 18 males aged 
between 19-27 years old (M=21, SD=2.3). As reimbursement for time and travel 
costs, participants received $80. First year psychology students could receive a 
combined reimbursement of $40 and four hours course credit. Participants were 
excluded if they were regular smokers, currently using psychoactive medication, 
daily paracetamol/ibuprofen users, or had illicit substance use that was recent (<6 
weeks) or notable (>10 lifetime uses). Participants were also excluded if they had a 
history of medical, neurological or mental disorders. Those who indicated potential 
alcohol abuse or dependence were excluded (scores > 16 on the Alcohol Use and 
Disorders Identification Test [AUDIT]; Babor, Higging-Biddle, Saunders, & 
Monteiro, 2001). Additionally, participation was not permitted for those 
experiencing high levels of psychological distress (score >30 on the Kessler 
Psychological Scale [K10]; Andrews & Slade, 2001) or those at risk of psychosis 
(scores >1 on the Psychosis Screener; Degenhardt, Wall, Korten, & Jablensky, 2005 
and/or scores >17 on the Schizotypal Personality Questionnaire-Brief [SPQ-B]; 
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Raine & Benishay, 1995). To reduce the chance of adverse reactions to modafinil, 
participants were required to have a moderate caffeine intake (1-7 times weekly) and 
a body mass index >18 (unlikely to be underweight).  
Materials and Apparatus  
Screening questionnaires.  
The Alcohol Use Disorders Identification Test (AUDIT). The AUDIT is a 
measure of alcohol abuse and dependence with strong validity (Babor et al., 2001; de 
Meneses-Gaya, Zuardi, Loureiro, & Crippa, 2009). It has eight items addressing 
frequency of alcohol consumption on a five-point scale and two addressing severity 
of the behaviour on a three-point scale. A score > 16 indicates potential problematic 
alcohol use (Babor et al., 2001). 
The Kessler Psychological Distress Scale (K10). The K10 is a 10-item 
questionnaire that offers an indication of global psychological distress (Andrews & 
Slade, 2001). This measure is reliable and valid for identifying the presence of a 
current mental disorder (Cornelius, Groothoff, van der Klink, & Brouwer, 2013). The 
questions are based on frequency of feelings of depression and anxiety over the past 
month (e.g. “how often did you feel hopeless?”). Responses are given on a scale 
from 1 (None of the time) to 5 (All of the time). Those who score >30 are considered 
to be at a high risk of psychological distress. 
The Psychosis Screener. The Psychosis screener is a four-item (plus two sub-
items) questionnaire used to identify people at risk of psychosis (Degenhardt et al., 
2005). The questions are in regard to whether the respondent has ever experienced 
serious symptoms of psychosis, which they may respond to with ‘Yes’ or ‘No’. This 
measure has a strong ability to identify participants experiencing symptoms at a 
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diagnostic level (Degenhart et al., 2005). Any ‘Yes’ response is considered indicative 
of psychosis risk. 
The Schizotypal Personality Questionnaire-Brief (SPQ-B). The SPQ-B can 
be used to identify the presence of schizotypal personality traits with acceptable 
internal consistency (Raine & Benishay, 1995). It contains 22 true-false items that 
fall within three domains; cognitive-perceptual, disorganised and interpersonal. A 
point is given for each “true” response, with higher scores indicating high 
schizotypy. Those who score >17 are considered to be at a high risk of psychological 
distress.  
Demographic Measures. 
The Wechsler Test of Adult Reading (WTAR). The WTAR is a measure of 
verbal intelligence that is a strong predictor of full-scale IQ (Wechsler, 2001; Green 
et al., 2008). It is comprised of 50 irregularly spelled words that the participant is 
asked to pronounce. A point is given for each correct pronunciation, with higher 
scores indicating higher intelligence.  
Wakefulness and Affect Measures. Wakefulness and affect measures were 
completed at baseline and post-ingestion of 200mg modafinil/placebo for each 
session, with the exception of the VAS for Subjective Drug Effects, which was only 
collected post-ingestion. 
The Karolinska Sleepiness Scale (KSS). The KSS is a subjective measure of 
present fatigue. The nine-point scale ranges from ‘extremely alert’ to ‘extremely 
sleepy-fighting sleep’, with higher scores indicating greater fatigue.  
Profile of Mood States- Short Form (POMS-SF). The POMS-SF (Shacham, 
1983) was used as a subjective measure of mood. It is self-administered, requiring 
participants to rate their present experience of 37 adjectives on a 5-point Likert scale 
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(from 0=not at all to 4=extremely). This results in a Total Mood Disturbance score 
(ranging from 0-148), as well as scores for subscales; Tension-Anxiety (0-24), 
Depression- Dejection (0-32), Anger-Hostility (0-28), Vigour-Activity (0-24), 
Fatigue-Inertia (0-20), Confusion-Bewilderment, (0-20). Higher scores are indicative 
of higher mood disturbance.  
Visual Analogue Scales (VAS). VAS were used as a subjective measure of 
perceived ability to perform attentional tasks and drug effects (Hartley, 2011). Each 
VAS consisted of four statements, which the participants indicated their degree of 
agreement with by marking a position along a 10cm horizontal line. The distance 
(cm) from the beginning of the line to the marked point was measured and used as 
the score for each statement (ranging 0-10). The two end-points indicated strongly 
disagree (0) and strongly agree (10) for the Subjective Performance VAS. The four 
Subjective Performance VAS statements included feelings of alertness, ability to 
perform attentional tasks, unimpaired driving ability and capacity to drive safely. 
The statements for the Subjective Drug Effects VAS related to strength and liking of 
the drug, levels of alertness and intoxication.  
The Revised Attentional Network Task (ANT-R). 
The ANT-R task was based on Neuhaus et al., 2010 and stimuli were 
presented on an 18-inch screen using NeuroScan STIM 3.1 software (see figure 1). 
Instructions appeared before each trial began. All instructions and stimuli were white 
and appeared on a black background.  
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Figure 1. An illustration of the ANT-R (adapted from Neuhaus et al., 2010).  
 
The task began with 10 practice trials in both versions. The baseline test 
phase consisted of 192 randomly ordered trials in a single block (9.76 minutes). The 
experimental test phase consisted of 576 randomly ordered trials in four blocks with 
breaks to minimise fatigue (39 minutes plus breaks). A fixation point (white dot) 
appeared in the centre of the screen throughout the task. After the instructions, one of 
three equiprobable cue stimuli (no cue or an asterisk, .387cm in length) appeared for 
100ms. For the central, alerting cue, an asterisk was presented directly on top of the 
fixation point. For the spatial cue it was presented 1.01 degrees above or below the 
fixation point. Spatial cues always validly predicted the upcoming location of the 
target. After the cue stimuli, the target stimuli appeared, comprising of five arrows in 
a horizontal row (3.4cm long). The participant’s task was to indicate the direction of 
the centre arrow using a left or right button press with their respective index fingers, 
on a NeuroScan response pad. Arrows adjacent to the central target were either 
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pointing in the same direction (congruent) or pointing in the opposite direction 
(incongruent). Responses were collected between 150-1500ms post-target. 
The original task included a double cue as well as a neutral flanker option. In the 
current task, the central cue replaced the role of the double cue as they were both 
alerting cues that were not notably statistically or theoretically different (Neuhaus et 
al., 2010). As the executive network was not the focus of the current study, the 
neutral flankers were also removed to increase the number of trials. The inclusion of 
the congruent and incongruent flanker was sufficient to identify flanker effects. The 
original task also had variable inter-trial intervals that were jittered (1,200ms, 
1,100ms, 1,000ms, 900ms excluding the response window) in the current study for 
programming ease. 
Electrophysiological Recording. A NeuroSCAN system and 32-channel Quik 
cap were applied to record eletrophysiological activity. Continuous EEG data was 
recorded from 32 sites according to the 10-20 system of electrode placement. 
Electrodes were referenced to the mastoids and electrode impedance was kept below 
10kΩ. Horizontal electro-occulographic (EOG) activity was recorded at the outer 
canthi of both eyes and vertical EOG was recorded above and below the left eye. 
Data was sampled at a rate of 1000Hz and averaged offline for a 1000ms epoch 
commencing 100ms prior to stimulus presentation. 
The behavioural and continuous EEG data were merged together for editing. 
They were filtered using a Zero-phase-shift low pass filter (30Hz, 24 dB/Oct). To 
reduce the influence of eye blinks on the electrode channels ocular artefact reduction 
was conducted. Next, epoch extraction was set from -100-900ms post target stimulus 
onset. An automated baseline correction was applied as well as an artifact rejection, 
set at 70 microvolts. The occipital N1 component was derived from grand averaged 
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waveforms and defined as the maximum amplitude between 80-140ms from the 
onset of the targets. These peaks were derived using an automatic peak picking 
procedure and followed with visual inspection. Changes were only made if the peak 
fell slightly outside the allocated time window.   
Procedure 
The University of Tasmania Health and Medical Human Research Ethics 
Committee approved the project (Appendix A). Each participant voluntarily gave 
written informed consent (Appendix B, C, & D). After they contacted the 
researchers, a preliminary screening interview was conducted over the phone 
regarding age, smoker status, caffeine intake, BMI, drug and medical history, current 
medications, as well as brief versions of the AUDIT, SPQ and K10 (Appendix E). A 
more comprehensive screening questionnaire was self-completed at the beginning of 
their first experimental session (Appendix F). Eligible participants completed two 
four-hour sessions, at least one week apart to avoid residual effects of modafinil. To 
control for fatigue due to circadian rhythm all sessions were conducted between 12-
5pm. Prior to each session, the researcher confirmed that the participant was being 
collected by someone else, rather than driving. Participants were told to have a light 
meal before each session, consume caffeine as usual, and abstain from 
paracetamol/ibuprofen and alcohol for 24-hours before and after each session. In 
case of any adverse reactions, the researchers were first-aid trained and reminded 
participants to seek a doctor, if necessary, post-experiment. 
Sessions differed by capsule condition (200mg modafinil or placebo), which 
was counterbalanced across participants by a researcher who was absent during the 
experimental sessions. The study was double blind, with experimental researchers 
receiving the capsules in envelopes labelled with participant and session numbers. 
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Pre-ingestion, participants self-completed the experimental questionnaire. For 
session one, this included demographic information as well as the extended screening 
(the full SPQ, K10 and AUDIT). For both sessions, participants reported their 
morning caffeine and food intake and completed measures of mood (POMS-SF, see 
Appendix G), subjective wakefulness (the KSS and VAS, see appendix H and I), and 
the baseline ANT-R. After capsule ingestion, participants had a waiting period to 
allow for drug absorption. They read, studied, or watched television in a private 
room for two hours before being setup for electrophysiological recording. Previous 
research indicates that plasma levels peak 2-4 hours post-ingestion of modafinil 
(Minzenberg & Carter, 2008). Two and a half hours post-ingestion, participants 
began two computer tasks including the experimental ANT-R, in a counterbalanced 
order. Tasks took approximately 50 minutes. Participants were requested to respond 
to the tasks both accurately and quickly, whilst minimising their eye and body 
movements. Afterwards, they completed post-ingestion measures of subjective 
wakefulness (the KSS and VAS), mood (POMS), drug effects (VAS, see appendix 
J), as well as a side effects checklist (see appendix K). Finally, they offered a 
certainty rating from 0-100% as to whether they had consumed the active drug that 
session. The second session followed the same format. Finally, each participant was 
debriefed, thanked and received compensation for their time (monetary 
reimbursement and/or course credit).  
Design and Data Analysis 
The assumptions of ANOVA were checked to ensure the data was 
appropriate for this analysis. One participant was identified as a consistent outlier for 
most cue types in the RT analysis, but was retained in analyses as preliminary 
analysis showed that their results did not significantly influence the main effects and 
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interactions. Two separate 3x2x2x2x2 repeated measures ANOVAs were conducted 
to analyse the effect of Cue type (central, spatial or no cue), Drug (modafinil or 
placebo), Time (baseline or post consumption), and Congruency (congruent or 
incongruent) on reaction time (milliseconds) and accuracy (as a percentage of correct 
responses). For these measures, planned comparisons were conducted to assess the 
effect of drug over time for each cue type.  
The electrophysiological dependent variable was target locked peak 
amplitude of the N1 ERP component. N1 amplitude was analysed at the left (O1) and 
right (O2) occipital electrode sites. A third repeated measures ANOVA was 
conducted to analyse the amplitude of the N1 ERP component with the additional 
variable of site (O1 or O2) and without the variable of time, as ERP data was only 
collected post-ingestion. For N1 amplitude, planned comparisons were conducted to 
assess the effect of drug by cue.  
A series of paired-samples t-tests were conducted to check for differences in 
control variables (caffeine, sleep, fatigue, alertness, POMS-SF total and subscales) at 
baseline. Paired-samples t-tests were also conducted to analyse whether Subjective 
Drug Effects (VAS reports of strength, liking, alertness and intoxication) at post-
ingestion were significantly different between drug conditions.  
Four separate 2x2 repeated measures ANOVAs were conducted to analyse 
each of the Subjective Performance ratings (VAS reports of alertness, attention 
ability, unimpaired driving and driving safe) by Drug (placebo, modafinil) and Time 
(baseline and post-ingestion). Six separate 2x2 repeated measures ANOVAs were 
conducted to analyse each of the POMS-SF subscale ratings (Tension-Anxiety, 
Depression-Dejection, Anger-Hostility, Vigour-Activity, Fatigue-Inertia and 
Confusion-Bewilderment) by Drug (placebo, 200mg modafinil) and Time (baseline 
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and post-ingestion). The main effects of Drug and Time on participants certainty (0-
100%) that they had taken modafinil was analysed with a related-Samples Wilcoxon 
signed Rank Test.  
For all dependent variables, only main effects and interactions that were 
hypothesis relevant or related to Drug are reported. As the variable of Cue had three 
levels, sphericity was not assumed and Greenhouse-Geisser corrections were applied 
for effects involving this variable. Partial-eta squared clarified effect sizes for 
omnibus ANOVAs. For tests of simple effects, Hedges g was applied, as it 
accommodates for smaller sample sizes compared with Cohen’s d, and was 
interpreted as 0.2=small, 0.5=moderate, 0.8=large (Cohen, 1991).  
Results 
Demographic and Screening Variables 
All participants were fluent English speakers who had completed year 12, 
with most (89.9%) enrolled in university at the time of testing. They were 
predominantly of average intelligence (WTAR) and fell within a healthy weight 
range (BMI), with some variability. None of the sample indicated problematic levels 
of alcohol use (AUDIT), risk of psychosis (SPQ) or psychological distress (K10) 
(Table 2). 
Manipulation Check 
A Related-Samples Wilcoxon signed Rank Test indicated that participants 
were significantly more certain that they had consumed modafinil in the active 
condition (M=48.3, SD=34.93) compared with the placebo condition (M=21.6, 
SD=25.5), Z=2.31 p=.021. 
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Table 2   
Mean Age, BMI and Raw Scores for Demographic and Screening Variables 
Variable M (SD) Range 
Age (years) 21 (2.3) 8 
BMI 23 (4.2) 16 
Problematic Alcohol Use (AUDIT) 3.8 (3.0) 10 
Risk of Psychosis (SPQ) 3.5 (4.9) 17 
Psychological Distress (K10) 13.2 (4.9) 15 
General Intellectual Functioning (WTAR) 35.7 (5.9) 22 
Note: for more detail around these variable measures including cutoffs, see 
method. 
 
Baseline Measures 
At baseline, participants indicated no significant differences on several 
confounding variables including caffeine intake, alertness (VAS), fatigue (KSS) and 
mood (POMS), between drug conditions (See Table 3). 
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Table 3 
Group Means, Standard Deviations in Parentheses, and Paired Samples T-Test 
Results for Control Variables at Baseline 
 
Baseline Measure 
 
 
Modafinil  
M (SD) 
 
Placebo 
M (SD)  
 
t 
(1,17) 
 
p 
 
g 
 
Caffeine Intake 
 
0.5 (0.9) 
 
0.6 (0.8) 
 
.809 
 
.430 
 
0.33 
 
Sleep (Hours) 
 
7.5 (1.1) 
 
7.7 (1.2) 
 
.732 
 
.474 
 
0.17 
 
Fatigue (KSS) 
 
4.7 (1.0) 
 
4.7 (1.2) 
 
.181 
 
.859 
 
0.04 
 
Alertness (VAS) 
 
3.6 (1.3) 
 
3.7 (1.3) 
 
.486 
 
.633 
 
0.08 
      
POMS-SF (Total mood 
disturbance) 
17.7 (10.9) 17.1 (10.5) .485 .634 0.05 
      
POMS-SF subscales      
      
    Tension-Anxiety 3.0 (3.5) 2.9 (3.6) .140 .891 0.03 
      
    Depression-Dejection 1.3 (2.1) 1.2 (2.2) .334 .742 0.05 
      
    Anger-Hostility 0.3 (1.2) 0.3 (0.7) -.251 .805 0.00 
      
    Vigour-activity 8.5 (5.9) 8.6 (4.6) -.169 .868 -0.02 
      
    Fatigue-Inertia 2.8 (2.8) 1.9 (2.0) 1.699 .108 -0.36 
      
    Confusion-Bewilderment 1.8 (2.2) 2.1 (3.1) -.531 .602 -0.11 
      
Note: For caffeine intake means represent the number of relevant products consumed 
prior to the session. 
 
Mood (POMS-SF) 
There was a significant Drug x Time interaction for the Depression-
Dejection, Vigour-Activity and Fatigue-Inertia subscales of the POMS-SF (see 
Tables 4 and 5). Planned comparisons indicated a significant decrease in Vigour-
Activity and increase in Fatigue-Inertia between baseline and post-ingestion for 
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placebo but no significant change for modafinil. Furthermore, at post-ingestion, 
participants reported significantly lower Vigour-Activity after placebo, compared 
with modafinil, p=.002, g=1.04. There was a significant decrease in Depression-
Dejection between baseline and post-ingestion for modafinil, but no significant 
change for placebo. For mood, all other differences between modafinil and placebo 
at post-ingestion were not significant, p>0.05 (See Appendix L, Table 6). 
Subjective Performance and Subjective Drug Effects 
There was a main effect of Time on subjective performance components 
relating to driving ability (see Table 7). Across drug conditions, participants were 
less inclined to agree that they felt able to drive unimpaired or safely at post-
ingestion compared with baseline (see Table 8). There was a significant Drug x Time 
interaction for the Alertness and Attention Ability components of the VAS. Planned 
comparisons indicated a significant decrease in Subjective Alertness and Attentional 
Ability between baseline and post-ingestion for placebo, but not for modafinil. 
At post-ingestion, participants reported significantly stronger drug effects for 
modafinil (M=36.3, SD=29.5) compared with placebo (M=20.4, SD=21.7), 
t(17)=2.15, p=0.46, g=0.60. They also reported higher liking for modafinil (M=57.5, 
SD=20.6) compared with placebo (M=40.5, SD=20.0), t(17)=2.79, p=.012, g=0.82 
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Table 4  
Differences between baseline and post-ingestion fatigue and mood within each drug condition  
 Modafinil Placebo 
Measures Baseline Post p g Baseline Post p g 
Fatigue (KSS) 4.72 (1.02) 4.22 (1.73) .077 0.34 4.67 (1.24) 6.11 (1.41) .608 0.26 
POMS-SF subscales:         
Tension-Anxiety 3.00 (3.46) 3.72 (5.07) .520 0.16 2.89 (3.60) 2.00 (2.95) .252 1.06 
Depression-Dejection 1.33 (2.09) 0 (0) .015 0.88 1.22 (2.21) 1.28 (3.27) .933 0.02 
Anger-Hostility 0.28 (1.18) 0.06 (0.24) .449 0.25 0.33 (0.69) 0.28 (0.96) .854 0.06 
Vigour-Activity 8.50 (5.92) 9.83 (6.21) .325 0.21 8.61 (4.59) 4.44 (3.62) <.001 0.99 
Fatigue-Inertia 2.83 (2.81) 4.28 (3.37) .184 0.46 1.94 (2.01) 6.44 (4.63) <.001 1.23 
Confusion-Bewilderment 1.78 (2.16) 1.83 (2.92) .917 0.02 2.06 (3.08) 2.33 (3.12) .523 0.09 
Note: Post refers to Post-Ingestion  
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Table 5 
Interactions and Main Effects of Drug and Time for Mood Measures 
 Drug Time Drug x Time 
POMS-SF Subscales F  p η2p F  p η2p F p η2p 
Tension-Anxiety 3.49  .079 .170 0.02 .901 .001 1.45 .245 .079 
Depression-Dejection 1.35 .261 .074 1.74 .205 .093 4.83 .042 .221 
Anger-Hostility 1.00 .331 .056 0.30 .593 .017 0.35 .564 .020 
Vigour-Activity 8.86 .008 .343 3.34 .085 .164 15.7 .001 .480 
Fatigue-Inertia 1.50 .238 .081 16.6 .001 .494 4.90 .041 .224 
Confusion-Bewilderment 1.69 .210 .091 0.20 .664 .011 0.14 .712 .008 
Note: Degrees of freedom 1, 17 for all.  
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Table 7 
Interactions and Main Effects of Drug and Time for Subjective Fatigue and Performance Measures 
 Drug Time Drug x Time 
Measures F  p η2p F  p η2p F p η2p 
KSS 12.8 .002 .429 2.70 .118 .137 9.60 .007 .360 
VAS Subjective Performance 
Subscales: 
         
Alert  (1) 11.1 .004 .395 0.50 .490 .028 7.94 .012 .318 
Attention Ability (2) 7.56 .014 .308 13.0 >.001 .577 8.71 .009 .339 
Driving Unimpaired (3) 0.73 .404 .041 17.0 .002 .433 2.07 .169 .108 
Driving Safe (4) 0.18 .679 .010 23.2 .001 .500 0.001 .981 .000 
Note: Degrees of freedom 1, 17 for all.  
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Table 8       
Subjective Performance Ratings at Baseline and Post-Ingestion by Drug   
 Modafinil Placebo 
Subjective 
Performance 
Baseline Post p Baseline Post-
Ingestion 
p 
Alert   3.63 (1.09) 2.89 (2.16) .189 3.74 (1.45) 5.08 (2.11) .034 
Attention 
Ability  
2.34 (1.26) 2.84 (2.24) .307 2.58 (1.16) 4.84 (2.03) <.001 
Driving 
Unimpaired  
1.47 (2.38) 2.97 (2.56) .019 1.45 (2.12) 3.81 (3.04) .002 
Driving 
Safe  
9.61 (1.88) 2.63 (2.86) .003 1.12 (2.26) 2.81 (2.92) .010 
Note: Degrees of freedom 1, 17 for all. 
 
  
 34 
 
Table 9 
Percentage of Participants who Reported Side Effects by Drug Condition  
Side Effects Placebo (%) Modafinil (%) p 
Headache 16.7 5.6 .625c 
Nausea 11.1 0 N/A 
Dry Mouth 11.1 38.9 .063 
Runny Nose 5.6 0 N/A 
Sore Throat 0 0 N/A 
Nervousness 5.6 11.1 N/A 
Dizziness 11.1 16.7 1.000c 
Note: Significance = Mcnemar value. 
Reaction Time 
For RT descriptive statistics see Table 10. There was a large and significant 
main effect of Cue on RT, F(1.55,26.39) =250.8, p<.001, η2p=.951. Overall, 
participants responded slowest to the target when no cue was provided (M=512.6, 
SD=35.9) faster when it was preceded by an alerting cue (M=494.6, SD=35.0) and 
fastest after a spatial cue (M=439.6, SD=31.4). Pairwise comparisons indicated these 
differences between cues were all significant (all ps <.001). Overall, participants 
were significantly faster when responding to congruent (M=444.72, SD=35.00) 
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compared with incongruent trials (M =519.79, SD = 33.99), F (1, 17) =279.426, p 
< .001, η2p=.943. 
 
Table 10 
Means for Reaction Time (ms) by Drug, Congruency, Cue and Time 
   Baseline Post-Ingestion 
Drug Congruency Cue M SD M SD 
Modafinil Congruent NC 475.7 60.2 469.9 35.7 
  CC 453.4 52.0 441.5 34.2 
  SC 410.4 43.6 399.5 29.1 
 Incongruent NC 552.3 52.8 544.7 36.1 
  CC 550.9 52.9 522.1 32.5 
  SC 477.2 56.7 457.7 30.4 
Placebo Congruent NC 473.2 45.5 487.1 48.2 
  CC 445.3 48.4 457.0 46.3 
  SC 415.1 42.3 408.5 41.9 
 Incongruent NC 533.8 42.5 564.0 51.5 
  CC 544.7 50.8 542.2 57.8 
  SC 471.8 46.7 476.1 57.3 
Note: NC = No Cue; CC = Central Cue; SC = Spatial Cue 
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The Cue x Congruency interaction was also significant, F(1.70, 
28.85)=34.32, p <.001, η2p=0.669. While RT decreased significantly with cue 
informativity for both congruent and incongruent trials, ps<.001, the difference 
between no cue and central cue conditions (alerting effect) was of moderate 
magnitude, g=0.67, for congruent trials, and of small magnitude for incongruent 
trials, g=0.24. The difference between central and spatial cues (orienting effect) was 
large for both congruent, g=1.9, and incongruent, g=1.9, trials. 
There were non-significant main effects of Drug, F(1,17)=.296, p=.594, 
η2p=.017, and Time, F(1,17) =0.173, p=.683, η2p=.010. However these effects were 
qualified by a significant Drug x Time interaction, F(1, 17)=4.54, p=.048, η2p=.211. 
Pairwise comparisons indicated a non-significant difference between baseline 
compared with post-ingestion for the placebo condition, p=.151, g=0.19, and a small 
but non-significant decrease for the modafinil condition p=.280, g=0.34. At baseline, 
there was a non-significant difference between the modafinil and placebo, p=.658, 
g=0.12, conditions. However, at post-ingestion, there was a moderate magnitude 
effect which approached significance, with lower RT for modafinil compared with 
placebo, p=.064, g=0.41. 
The hypothesised Drug x Time x Cue interaction was non-significant, F(1.63, 
27.72)=2.418, p=.116, but had a moderate effect size, η2p=.125 (see Figure 1).  
Planned pairwise comparisons were conducted to assess the effect of Drug over Time 
for each Cue type. When the target was preceded by no cue, between baseline and 
post-ingestion there was a small, significant increase in RT for placebo, p=.011, 
g=0.48, but no significant change for modafinil, p=.536, g=0.14. Furthermore, at 
post-ingestion, RT was shorter for modafinil compared with placebo (M=525.58, 
SD=11.27), p=.030, g=0.71. 
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When the target was preceded by a central cue, there was a small, significant 
decrease in RT between baseline and post-ingestion for modafinil, p=.040, g=0.33, 
but no significant change for placebo, p=.541, g=0.09. For central cue trials, there 
was a trend towards faster RT at post-ingestion for modafinil compared to placebo, 
p=.071, and this was a small effect, g=0.43.When the target was preceded by a 
spatial cue, there was a small but non-significant decrease in RT between baseline 
and post-ingestion for modafinil (p=.136, g=0.37), but no significant change for 
placebo (p=.892, g=0.03). For spatial cue trials, there was a small but non-significant 
decrease in participants RT at post-ingestion for modafinil, compared with placebo, 
p=.158, g=0.34). 
 
Figure 1. Reaction Time at Baseline and Post-Ingestion by Cue and Drug (error bars 
indicate 95%CIs) 
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There was also a significant Drug x Time x Congruency interaction, 
F(1,17)=3.088, p=.002, η2p=.435 (see Figure 2 and Figure 3). Further analysis 
indicated a significant Drug x Time interaction for incongruent trials, F(1,17)=6.732, 
p=.019, η2p=.284, but not for congruent trials, F(1,17)=2.415, p=.139, η2p=.124. For 
incongruent trials in the modafinil condition, there was a small-moderate decrease in 
RT at post-ingestion compared with baseline that was trending towards significance, 
p=.096, g=0.43. However, for incongruent trials in the placebo condition, there was a 
small non-significant difference in reaction time at baseline compared with post-
ingestion, p=.265, g=0.21.  
 
Figure 2. Mean Reaction Time (ms) for targets following congruent cues at baseline 
and post-ingestion for the modafinil and placebo conditions (error bars represent 
95% CIs). 
 
  Furthermore, for incongruent trials, there was a small decrease in RT for 
modafinil compared with placebo at post-ingestion that was trending towards 
significance, p=.061, g=0.43. For incongruent trials, there was a small, but non-
significant difference between modafinil and placebo RT at baseline p=.497, g=0.20. 
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Figure 3. Mean Reaction Time (ms) for targets following incongruent cues at 
baseline and post-ingestion for the modafinil and placebo conditions (error bars 
represent 95% CIs). 
 
Accuracy  
For accuracy, descriptive statistics are shown in Table 11. The main effects of 
Cue, F(1.73,29.40)=18.92, p<.001, η2p=.527, Congruency, F(1,17)=52.21, p<.001, 
η2p=.754, and the interaction between the two, F(1.88,31.9)=12.09, p<.001, 
η2p=.416, were all significant.  
For congruent trials, accuracy was significantly higher after spatial cues 
compared with no cue, p=.013, g=0.34, and central cues, p=.001, g=0.24. For 
congruent trials, accuracy was not significantly different for trials preceded by no 
cue compared with central cues, p=.202, g=0.13. 
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Table 11 
Means for Accuracy  (as a percentage) by Drug, Congruency, Cue and Time 
   Baseline Post-Ingestion 
Drug Congruency Cue M SD M SD 
Modafinil Congruent NC 94.5 15.8 97.1 4.2 
  CC 94.6 15.5 97.9 3.1 
  SC 95.4 15.6 98.3 2.6 
 Incongruent NC 90.9 15.1 93.6 4.5 
  CC 89.4 16.1 91.0 6.9 
  SC 93.1 15.7 96.2 2.8 
Placebo Congruent NC 98.1 2.4 96.2 3.9 
  CC 97.9 4.6 96.3 3.4 
  SC 97.1 4.6 97.2 3.6 
 Incongruent NC 93.9 6.3 90.9 6.1 
  CC 94.4 4.4 88.8 6.0 
  SC 96.7 3.5 94.3 5.3 
Note: NC = No Cue; CC = Central Cue; SC = Spatial Cue 
 
For incongruent trials, accuracy was moderately and significantly higher after 
spatial cues, compared with no cue p=.001, g=0.77, and central cues, p<.001, g=1.18. 
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For incongruent trials, accuracy was moderately and significantly, higher for trials 
preceded by no cue compared with central cues, p=.004, g=0.48. For accuracy, there 
were no other significant main effects or interactions (ps>.05, see Appendix M, 
Table 12). 
Peak N1 Amplitude 
Figure 4 shows grand mean averaged ERP waveforms for target locked trials for 
each of the three cue-type conditions. See Table 13 for the descriptive statistics for 
N1 amplitude to the target.  
 
Figure 4. Grand Means for Target Locked N1 ERP Amplitude for Congruent Trials 
by Cue Type.  
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Table 13 
Mean Peak N1 Amplitude to Targets by Site, Congruency and Cue 
   Modafinil Placebo 
Site Congruency Cue Mean SD Mean SD 
01 Congruent NC -2.48 3.37 -1.95 2.86 
  CC -4.65 3.79 -4.06 3.56 
  SC -7.55 3.63 -6.94 4.12 
 Incongruent NC -2.71 3.51 -1.98 3.06 
  CC -4.46 4.10 -3.64 3.75 
  SC -7.51 4.14 -6.85 3.56 
02 Congruent NC -1.96 2.03 -1.49 2.04 
  CC -4.36 2.44 -3.49 2.34 
  SC -6.50 2.96 -6.04 3.40 
 Incongruent NC -2.01 2.24 -1.69 2.20 
  CC -3.91 2.91 -3.27 2.88 
  SC -6.61 3.18 -5.79 2.72 
Note: NC = No Cue; CC = Central Cue; SC = Spatial Cue.  
 
There was a significant main effect of cue on N1 amplitude, 
F(1.5,25.8)=64.25, p<.001, η2p=.793. There was a large, significant increase in 
target locked N1 amplitude for spatial cues (M=-6.7 SD=2.9) compared with central 
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cues (M=-3.9, SD=3.0), p<.001, g=0.87, and no cues (M=-2.0, SD=2.5), p<.001, 
g=1.85. There was also a moderate, significant increase in N1 amplitude for central 
cues compared with no cue (g=0.69). The main effect of drug approached 
significance, with greater N1 amplitude for the modafinil condition (M=-4.6, 
SD=2.8) compared with placebo (M=-3.9, SD=2.7), F(1,17)=3.06, p=.098, g=0.25.  
The hypothesised Drug x Cue interaction was non-significant, 
F(1.6,27.7)=0.14, p=.833, η2p=.008 (see Figure 5). Planned comparisons were 
conducted to analyse any differences in N1 amplitude by cue type. They revealed 
that when preceded by central cues, there was a small, significant enlargement of 
target locked N1 amplitude for the modafinil compared with the placebo condition, 
p=.046, g=0.23. Similarly, when the target was preceded by no cue, the average N1 
amplitude was greater in the modafinil condition, compared with placebo. However, 
this effect was small and only trending towards significance, F(1,17)=3.61, p=.075, 
g=0.20. When the target was preceded by a spatial cue there was no significant 
difference in N1 amplitude between the modafinil condition, and the placebo 
condition, F(1,17)=1.09, p=.311, g=0.19. 
The Drug x Cue x Congruency x Site interaction was trending towards 
significance, F(1.7, 29.4)=2.61, p=.093, η2p=.133, but was not of interest to the 
current study. All other main effects and interactions were non significant (See 
Appendix N, Table 14). 
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Figure 5. N1 amplitude by Drug and Cue  
Discussion  
The present study investigated the effects of 200mg of modafinil on 
behavioural (reaction time and accuracy) and neural (N1 ERP component) measures 
of attentional alerting and orienting in healthy humans using an ANT-R paradigm. 
As hypothesised, RT decreased and N1 amplitude increased with cue informativity, 
across drug conditions. The results supported the hypotheses that if modafinil 
enhanced the alerting network, there would be a significantly greater reduction in RT 
and a significant increase in N1 amplitude following central cues, for the modafinil 
relative to the placebo condition. Furthermore, there was an unexpected enhancement 
of RT and N1 for no cue trials, for the modafinil relative to the placebo condition. 
These results indicate that modafinil may enhance the tonic and phasic components 
of the alerting network. There was an equivalent enhancement of the orienting 
network that was not greater than the alerting effects. The self-report data indicates 
that these effects of modafinil may have been the result of reduced feelings of fatigue 
experienced at post-ingestion. The accuracy analysis indicated no significant 
 45 
differences between the drug conditions, thus differences for RT between drug 
conditions cannot be accounted for by a speed-accuracy trade-off. 
The blinding procedure appears to have been successful. Within both 
conditions, participants tended to report low certainty (on a 0-100% rating) that they 
had consumed modafinil. They were significantly more certain in the active 
condition than for the placebo condition, but participants’ capacity to guess the 
correct condition was lower than chance (50%). Side effects did not differ 
significantly between conditions. 
Reaction Time 
As hypothesised, RT decreased with cue informativity; participants were 
slowest for no cue, faster for central cues and fastest for spatial cues Additionally, 
RT was slower for congruent relative to incongruent trials. The orienting effect was 
of similar magnitude for both congruencies, whilst the alerting effect was larger for 
congruent compared with incongruent trials. These effects indicate that the task 
elicited differences that were consistent with theorised attentional networks 
(Neuhaus et al., 2010).  
The results for the modafinil condition indicated a small, significant decrease 
in RT from baseline to post-ingestion for central cues (g=0.33) and a small, non-
significant decrease for spatial cues (p=.136, g=0.37). These findings may indicate 
enhancement of the alerting network for the modafinil condition relative to placebo, 
as expected. The results for the spatial cues indicate an enhancement of orienting 
between baseline and post-ingestion for modafinil in comparison with placebo. 
However, this effect was not significant, nor greater in magnitude than the central 
cue effect. This negates the alternative hypothesis that if modafinil directly enhances 
the orienting network, there would be a significantly greater reduction in RT for 
 46 
targets between the central and spatial cues from baseline to post-ingestion for the 
modafinil condition relative to the placebo condition.   
The significant increase in RT for no cue trials at post-ingestion compared 
with baseline for placebo, but not modafinil, was not hypothesised. It may suggest 
that modafinil alleviated fatigue induced by the sustained nature of the task, 
enhancing tonic alertness. This is consistent with previous findings that modafinil 
enhances performance on sustained attention tasks, a marker of tonic alertness 
(Baranski et al., 2004; Theunissen et al., 2009, Randall et al., 2005). Baranski et al. 
(2004) observed enhanced sustained attention, demonstrated by improved accuracy 
on the DRN and faster RT on the SRT, when participants ingested modafinil 
compared with placebo. Similarly, Theunissen et al. (2009) found a large, significant 
reduction in RT for the MC task when participants consumed modafinil compared 
with placebo, indicating enhanced sustained attention. Randall et al. (2005) found 
that participants who received modafinil were faster on the RVIP compared to 
placebo controls. The findings of the current study are consistent with these 
observations that modafinil enhances tonic alertness. The results are inconsistent 
with previous studies that have reported no effect of modafinil on sustained attention 
(Liepert et al., 2004, Winder-Rhodes et al., 2010). These studies used simple 
attention tasks, likely eliciting ceiling effects as they were not cognitively 
challenging. In contrast, the current study incorporated incongruent flankers, 
increasing cognitive load and better allowing any enhancing effect of modafinil to be 
observable. Furthermore, the current sample was larger and more likely to 
experience enhancement as they had no nicotine dependence.  
The significant, small, g=0.33, decrease in RT between baseline and post –
ingestion for central cues in the modafinil condition suggests a further enhancement 
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for phasic alertness that is distinct to the enhancement of tonic alertness. Only one 
previous study has looked specifically at phasic alertness, and they found no 
enhancing effect of modafinil compared with placebo for no cue trials, g=0.14, or 
alerting cue trials, g=0.08 (Liepert et al., 2004). The current findings are likely more 
reliable due to the larger sample and more challenging task, which may have made 
the study comparably more sensitive to detecting small effects.  
Reduced RT to no cue trials indicates that modafinil may enhance tonic 
alertness, which may partially underlie the enhancement of phasic alertness. 
However, this effect was comparatively smaller and less significant than the effect 
observed for no cue trials. This is preliminary evidence that modafinil targets and 
enhances the tonic and phasic components of alerting attention. This seems to 
produce reduced RT to spatial cue trials (orienting) that is equivalent to the effects 
observed earlier and arguably the result of the interdependence of the attentional 
networks, as opposed to being a targeted effect of the drug. 
While not the main focus of the present thesis, there was a significant Drug x 
Time x Congruency interaction for RT, such that Drug x Time interaction was 
significant for incongruent trials but not congruent trials. For incongruent trials in the 
modafinil condition, there was a small-moderate decrease in RT at baseline 
compared with post-ingestion that was trending towards significance (p=.096, 
g=0.43), and this tended to be lower in comparison to placebo at baseline (p=.061, 
g=0.43). However, for placebo, there was a small non-significant difference in RT at 
baseline compared with post-ingestion, (p=.265, g=0.21). Thus it is possible that 
Modafinil increased participant’s capacity to inhibit the incongruent flankers, 
suggesting that modafinil enhances executive attention. Although unhypothesised, 
this is consistent with findings of enhanced executive functions for modafinil 
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compared with placebo, and the understanding that modafinil increases dopamine, a 
neurotransmitter that supports these functions (Geng et al., 2013). The original ANT-
R included a neutral target; a central arrow flanked with straight lines that were 
neither congruent nor incongruent. In the current study, neutral targets were omitted 
to maximise trials for each cue type, as executive attention was not the focus. Future 
research could better investigate these effects of modafinil on executive attention by 
incorporating neutral targets and comparing responses between neutral and 
incongruent trials to isolate the inhibitory control component of the task.  
N1 Component 
As hypothesised, N1 amplitude increased with cue informativity. This is 
consistent with previous findings for this task and indicates that it elicited the 
attentional networks as expected (Neuhaus, 2010). The drug x cue interaction was 
non-significant. Further analysis revealed a small, significant increase in N1 
amplitude for targets preceded by central cues for the modafinil condition compared 
with placebo. This is indicative of enhancement of phasic alertness, and consistent 
with the hypothesis that if modafinil has a direct effect on alerting there would be a 
greater significant increase in N1 amplitude for central cues for the modafinil relative 
to placebo condition.  
The results indicated no significant increase in N1 amplitude for spatial cues. 
This suggests that modafinil does not directly enhance the orienting component of 
attention. For no cue trials, there was an unexpected trend towards a significant 
increase in N1 amplitude for modafinil compared with placebo. This is potentially 
indicative of modafinil increasing tonic alertness which may have caused some of the 
increase in phasic alertness for modafinil compared with placebo. However, the 
magnitude of the enhancement was greater for central cues than for no cue and 
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spatial cues. This suggests that modafinil consumption may directly enhance tonic 
and phasic alertness.  
There is no previous research investigating the ERP correlates of attention 
relative to modafinil consumption. The N1 ERP component is known to index 
orienting towards and processing of stimuli (Näätänen & Michie, 1979; Vogel & 
Luck, 2000). The current results indicate modafinil may enhance this function as a 
consequence of improved functioning of both the tonic and phasic components of the 
alerting network, with some consequential enhancement of the orienting network. 
This is consistent with the behavioural results, which also indicated a potential 
increase in tonic and phasic alerting, as observed by decreased RT for no cue and 
central cue trials for modafinil compared with placebo. Furthermore, a similar 
enhancement of the orienting network was observed, demonstrated by an equivalent 
reduction in RT for spatial cue trials for modafinil but not placebo. The self-reports 
indicate that modafinil may have enhanced these areas of attention by alleviating the 
onset of fatigue and sleepiness experienced in the placebo condition.  
Modafinil and Mood 
Sleepiness (KSS) and Fatigue-Inertia (POMS-SF) increased between baseline 
and post-ingestion for placebo but not modafinil. Vigour-Activity decreased between 
baseline and post-ingestion for placebo, but not modafinil. Participants also reported 
feeling significantly less alert and capable of performing attentional tasks at post-
ingestion compared with baseline for placebo but not modafinil. These findings are 
consistent with the reputation modafinil has as a eugoroic and previous studies that 
have found modafinil improves performance on sustained attention tasks 
(Minzenberg & Carter, 2008)(Baranski et al., 2004; Theunissen et al., 2009, Randall 
et al., 2005). 
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Self-reported feelings of Depression-Dejection were low for both drug 
conditions, decreasing significantly between baseline and post-ingestion for 
modafinil but not placebo. This is consistent with the understanding that modafinil 
inhibits the re-uptake of dopamine, which promotes feelings of euphoria, and has 
seen modafinil trialled as an anti-depressant (Malhi et al., 2016; Regenthal, Koch, 
Kohler, Preiss, & Krugel, 2009). Unexpectedly, for both conditions, participants felt 
more capable of driving well at baseline compared with post-ingestion. Participants’ 
had been told not to drive home and indicating they were capable of doing so may 
have been perceived as defiant social behaviour, perhaps biasing their responses. 
Practical Implications 
The results of the current study suggest that modafinil may be effective for 
cognitive neuro-enhancement in healthy non-sleep deprived persons performing 
tasks that require high levels of tonic and phasic alertness, as well as executive 
attention. Despite the modafinil related enhancement of attention being small in 
magnitude and sometimes non-significant, for both RT and N1, it may be practically 
meaningful. This study also indicates that some orienting enhancement is observed 
after modafinil consumption, a small effect that can be attributed to the 
interdependent nature of the networks. As most off label-users tend to engage in 
tasks that are sustained, such as an air force officer watching a radar screen, the 
consumption of modafinil is likely to result in positive improvement in comparison 
with no drug. However, future research ought to compare the effects of modafinil 
with more well recognised cognitive neuro-enhancers such as caffeine, glucose and 
exercise (Benton, Owens & Parker, 1994; Brunyé,  Mahoney, Lieberman, & Taylor, 
2010; McMorris & Hale, 2012). It may be more practical for modafinil users to 
employ these enhancers if they are no less efficacious. Future research could also 
 51 
investigate whether enhancement is still observed in shorter tasks of phasic alerting, 
when fatigue is minimal. Furthermore, this study is only suggestive of small 
enhancing effects after a single dose of 200mg of modafinil. Future research also 
ought to investigate the effects of modafinil on specific networks of attention at 
differential and repeated dosages.   
Methodological Limitations 
Only males aged 18-30 were recruited, which limits the generalisability of the 
current findings to females and other ages. A male sample was chosen based on sex 
differences in the N1 component. In females completing the ANT-R, a significant 
frontal-occipital second peak of N1 has been observed that does not occur for males 
(Neuhaus et al., 2009). Sex differences have also been observed in cognitive 
processing and these may vary based on menstrual cycles (Brotzner, Klimesch, & 
Kerschbaum, 2015). Furthermore, the clearance rate for modafinil is faster for young 
compared with older males, and is faster again for young females (Wong et al., 
1999). This is suggestive of differential metabolic rates related to age and sex, 
indicating that performance enhancement may occur differentially for females and 
older populations. Future research should evaluate the efficacy of modafinil for 
neuro-enhancement in these groups.  
The current study was limited as peak plasma levels were estimated based on 
past studies rather than by collecting blood samples. Therefore, the time of testing 
may not have been ideal for each participant due to differences in absorption. 
Estimating peak plasma levels was less invasive for participants, however, future 
research with lighter ethical constraints could address this issue.  
The within-subjects design employed by the current study was both a strength 
and limitation. This design enabled participants to act as their own control for many 
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potential confounding variables (metabolic rate, stimulant tolerance, caffeine usage). 
As participants engaged with the task repeatedly, some degree of practice effects 
were suspected. Consequentially, baseline measures were taken to reduce their 
influence. Additionally, a preliminary mixed model analysis suggested that whilst 
practice effects had occurred, they did not supersede the effects of drug condition. 
This approach was chosen rather than incorporating order into the analysis as a 
between subjects variable because the study was already slightly underpowered due 
to sample size. As some practice effects were observed, future research may wish to 
carefully consider the susceptibility of their task to practice effects and choose a 
design accordingly.  
Baseline measures were not collected for comparison with post-ingestion data 
for N1 amplitude. The time cost associated with EEG setup for a brief baseline task 
was unfeasible for the current study. If future research has the scope, they may 
integrate baseline measures of ERP components. Such studies should also investigate 
other ERP components related to attentional enhancement due to modafinil 
consumption. The N200, which indexes the executive function of inhibitory control, 
would be of particular interest, as the behavioural results provided preliminary 
evidence of enhancement. 
Another limitation of the current study is that no eye tracking measurement 
was applied to check that the participants were focusing on the stimuli in the visual 
field as expected (Anderson, Nemrodov, Preston, & Itier, 2013). Participants were 
verbally instructed to focus on the fixation dot throughout the task and appeared to 
do so, given that the overall task effects for RT and N1 were consistent with previous 
research. However, future studies should utilise eye tracking to minimise type two 
errors (Anderson et al., 2013). 
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Summary and Conclusions 
The present study investigated the effects of 200mg of modafinil on 
behavioural (reaction time and accuracy) and neural (N1 ERP component) measures 
of attentional alerting and orienting in healthy humans using an ANT-R paradigm. 
The results indicated that regardless of drug condition, RT decreased and N1 
amplitude became greater with cue informativity, as hypothesised. This is tentative 
evidence that the task elicited the attentional networks (Neuhaus et al., 2010). 
For the modafinil condition, there was a small, significant, decrease in RT 
from baseline to post-ingestion for central cues that suggests alerting enhancement. 
The reduction in RT for spatial cues indicated an enhancement of orienting, likely a 
consequence of the alerting effect. The increase in RT for no cue trials for placebo 
but not modafinil further indicates that modafinil may have prevented reductions in 
tonic alertness. Given that the RT reduction was greater for central compared with no 
cue trials, it is likely that modafinil enhances phasic alertness.  
The N1 amplitude data further supported these arguments. Greater N1 
amplitude occurred for central cue trials for modafinil compared with placebo, 
suggesting the drug enhanced alertness. As amplitude was greater for no cue trials 
for modafinil compared with placebo, some of the alerting effect can be attributed to 
increased tonic alertness, but the magnitude was greater for central than no cue 
conditions compared, so modafinil also appears to directly enhance phasic alertness. 
The increase in N1 amplitude for spatial cues was not of a greater magnitude than 
that observed for central cues, indicating modafinil did not enhance orienting beyond 
the increase of alerting attention.  
The results of the current study are consistent with previous findings of tonic 
alerting enhancement for modafinil. However, the phasic alerting and orienting 
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effects are preliminary and novel, particularly for N1 amplitude. Further research is 
necessary to substantiate them. The finding that modafinil enhances executive 
alerting was not the focus of the current study and warrants investigation analysing 
the acute effects of modafinil on ERPs relevant to this network, such as N2. Any 
future studies also ought to address the limitations of the current study by 
investigating whether the findings can be generalised to females and other age 
groups with a design that improves on power by collecting blood plasma levels, eye 
tracking data, a greater sample size and collection of ERP data at baseline.   
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Appendix A: Ethics approval 
 
Sent via email 
 
From: Lauren.Black@utas.edu.au [mailto:Lauren.Black@utas.edu.au] 
Sent: Wednesday, 30 March 2016 1:22 PM 
To: Raimondo Bruno 
Cc: chris.wake@dhhs.tas.gov.au; Allison Matthews; Jessica Hartley; Lauren Black 
Subject: Notification of Amendment Approval: H0011386 The effect of modafinil on 
simulated driving performanc 
 
Dear AssocProf Bruno 
 
Ethics Ref: H0011386 
Title: The effect of modafinil on simulated driving performance 
 
This email is to confirm that the following amendment was approved by the Chair of 
the Tasmania Health and Medical Human Research Ethics Committee on 24/3/2016: 
 
Measurement of brain activity (EEG) during the experimental tasks Changes to the 
experimental tasks Omission of the baseline testing condition Registered nurse is no 
longer on site MODAFINIL info and consent forms_revised2016 
 
All committees operating under the Human Research Ethics Committee (Tasmania) 
Network are registered and required to comply with the National Statement on 
Ethical Conduct in Human Research (NHMRC 2007). 
 
This email constitutes official approval. If your circumstances require a formal letter 
of amendment approval, please let us know. 
 
Should you have any queries please do not hesitate to contact me. 
 
Kind regards 
 
Lauren Black 
 
-- 
Lauren Black 
Executive Officer - Ethics 
Office of Research Services 
University of Tasmania 
Private Bag 01 
Hobart TAS 7001 
Phone: (03) 6226 2764 
Fax: (03) 6226 2765 
Email: Lauren.Black@utas.edu.au 
Web: http://www.research.utas.edu.au/ 
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Appendix B: Information sheet 
 
INFORMATION SHEET 
 
The Effect of Modafinil on Cognitive Processes and Brain Activity 
 
Chief Investigators: Dr Raimondo Bruno & Dr Allison Matthews 
Researchers:  Caitlin Harris & Oliver De Angelis *  
*This research is being conducted as part of an Honours degree in the School of 
Psychology, UTAS. 
 
We would like to invite you to participate in a study aiming to better understand the 
way that the prescription drug Modafinil effects cognitive processes such as attention 
and associated brain activity. The use of this drug is increasing Australia wide, and we 
are interested in better understanding its effects. There have been a number of studies 
which have shown some effects of stimulant drugs on cognitive processes but very few 
studies have examined Modafinil. Getting a better understanding about Modafinil is 
particularly important, not just to understand how the drug affects cognition, but also 
to be able to provide information for doctors to give to potential users of the drug. 
 
Why have I been invited to participate in this research? 
You are invited to take part in the study if you are male and aged 18-30 years old. In 
order for the results of the study to be clear, all participants need to speak English 
fluently, and have had no previous neurological or mental health problems. In addition, 
participants must NOT use illicit drugs, smoke cigarettes daily, consume alcohol at 
harmful levels or be female. 
 
What will my participation involve? 
Participating in this study is unlikely to cause any discomfort or distress. Firstly, if you 
are interested in taking part in the study, you will be invited to complete a series of 
confidential screening questionnaires. These will enquire about what your mood has 
been like recently. This will include a psychological distress scale, schizotypal 
personality questionnaire, a psychosis screener and some questions regarding your 
alcohol, caffeine and drug use. All data collected will be kept in the strictest confidence, 
and the way we maintain this is described below. This screening process is simply to 
ensure that participants in the study are not taking medications or experiencing other 
issues that may cause a negative response to Modafinil.   
 
During the study, we will ask for some basic information about yourself (such as age, 
sex, years of schooling). During each testing session, you will be fitted with an electrode 
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cap for measuring your brain activity. You will be asked to complete some computer-
based tasks which relate to cognitive processes such as attention. In these tasks you 
will respond with a button press when particular stimuli appear on the screen. 
Previous studies using the same dose of Modafinil have found side effects for some 
participants, including dry mouth, mild headaches and mild nausea. There will be two 
testing sessions which will occur at the University of Tasmania, and will take around 
four hours each. You will be reimbursed up to $80 for your time and out-of-pocket 
expenses. 
 
Before taking part in the study you must organise for a reliable friend or family 
member to collect you from the lab at the end of the testing session, in case you are still 
experiencing any effects following the possible administration of Modafinil. The 
researcher will check that this has been organised before the testing session begins. 
When the nominated person collects you, they will be given a copy of the medication 
information sheet about Modafinil, and the main points will be verbally explained. 
Namely, it will be explained that they should ensure you do not drive a vehicle or 
operate machinery for the rest of the day, and do not consume alcohol. In the unlikely 
event that you do experience unpleasant side effects while completing the testing, the 
researchers are trained in first aid, and the chief investigators will be available on site 
to provide further assistance if required. Additionally, the researcher will explain that 
in the unlikely event of you experiencing an adverse reaction once you have left the 
premises, you should contact your doctor or be taken to hospital immediately. 
 
There are no specific risks associated with the measurement of brain activity. However, 
if you have sensitive skin there is a small possibility of a slight skin reaction from 
electrode preparation materials. If you believe there is a chance that your skin may 
react you are advised to reconsider participation. 
 
How private is the information that I give? 
It is important for you to know that all data collected will be kept in the strictest 
confidence. All data will be identified by a coding system and no names or contact 
numbers will appear on any records. In this way, your identity is protected, and there 
will be no risk of legal or social problems arising from your participating in the study. 
All information gathered in the study will be reported as grouped data, and because no 
personal information is recorded, no individual participants will be identifiable in the 
research output. Data from the study will be stored securely for five years in locked 
cabinets in the School of Psychology, as is legally required, and then destroyed by 
shredding. 
 
Can I withdraw from the research if I wish? 
Participation in this study is entirely voluntary. You may, at any time, decline to answer 
any question you so wish, or withdraw from the study without effect or explanation. 
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You will be given a copy of this information sheet to keep. Please retain this 
information sheet in case you decide at a later data that you would like to retract your 
data from the study.  
 
Who do I need to contact if I have any questions about the research? 
If you would like more information about the research, please contact Dr Allison 
Matthews on 62267236 (or email Allison.Matthews@utas.edu.au) or Dr Raimondo 
Bruno 6226 2190 (Raimondo.Bruno@utas.edu.au). If you would like to find out about 
the results of the study, these will be available from Dr Matthews after November 2016. 
 
Has this research been approved by an ethics committee? 
This project has been approved by the Tasmanian Health and Medical Human 
Research Ethics Committee. If you have any concerns of an ethical nature, or 
complaints about the manner in which the study is conducted, you may contact the 
Executive Officer of the Human Research Ethics Committee (Tasmania) Network on 
(03) 6226 7479 or human.ethics@utas.edu.au. Please quote the ethics reference 
number H0011386. 
Who can I contact if I have any concerns? 
If you have any personal concerns related to the study, you may choose to discuss these 
concerns confidentially with a counsellor at the University Psychology Clinic free of 
charge. Confidential appointments may be made on (03) 6226 2805. 
 
Thank you for your interest in the study and for taking the time to read this 
information sheet. We hope you will be interested in participating in this study. 
 
Raimondo Bruno & Allison Matthews  Oliver De Angelis/Caitlin Harris 
Chief Investigators                      Student Researchers   
(03) 6226 2190 or (03) 6226 7236 
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Appendix C: Consent form 
 
CONSENT FORM 
The Effect of Modafinil on Cognitive Processes and Brain Activity 
  
1. I have read and understood the 'Information Sheet' for this study. 
2.  I have read and understood the ‘Consumer Medicine Information’ regarding 
modafinil. 
2. The nature and possible effects of the study have been explained to me. 
3. I understand that the study involves: 
 Attending two testing sessions of approximately four hours duration 
 Completing a series of cognitive tasks while my brain activity is 
measured 
5. I understand that all research data will be securely stored on the University of 
Tasmania premises for five years, and will then be destroyed. 
6. Any questions that I have asked have been answered to my satisfaction. 
7. I agree that research data gathered from me for the study may be published 
provided that I cannot be identified as a participant. 
 
8. I understand that the researchers will maintain my identity confidential and that 
any information I supply to the researcher(s) will be used only for the purposes 
of the research. 
 
9. I agree to participate in this investigation and understand that I may withdraw 
at any time without any effect, and if I so wish, may request that any data I 
have supplied to date be withdrawn from the research. 
 
10. This project has been approved by the Tasmanian Health and Medical Human 
Research Ethics Committee. If you have any concerns of an ethical nature, or 
complaints about the manner in which the study is conducted, you may contact 
the Executive Officer of the Human Research Ethics Committee (Tasmania) 
Network on (03) 6226 7479 or human.ethics@utas.edu.au. Please quote the 
ethics reference number H0011386. 
  
Name of Participant: 
Signature: Date: 
 
Statement by Investigator  
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 I have explained the project & the implications of participation in it to 
this volunteer and I believe that the consent is informed and that he/she 
understands the implications of participation  
 
Name of investigator   
   
Signature of     investigator Date 
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Appendix D: Modafinil consumer medical information 
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 72 
Appendix E: Screening questionnaire 
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Psychosis Screener 
1. In the past 12 months, have you felt that your thoughts were being 
directly interfered with or controlled by another person? 
Yes      
No    
1a. Did it come about in a way that any people would find hard to 
believe, for instance, through telepathy? 
Yes      
No    
2. In the past 12 months, have you had a feeling that people were too 
interested in you? 
Yes      
No    
2a. In the past 12 months, have you had a feeling that things were 
arranged so as to have a special meaning for you, or even that harm 
might come to you? 
Yes      
No    
3. Do you have any special powers that most people lack? Yes      
No    
3a. Do you belong to a group of people who also have these special 
powers? 
Yes      
No    
4. Has a doctor ever told you that you may have schizophrenia?  Yes      
No    
Total= 
(≥1) 
 
Note to researchers:  
 
 Book sessions from 1-5pm 
 Remind participants to abstain from paracetamol/ibuprofen on the day of 
testing, and alcohol for 24hrs prior to testing 
 Stick to normal caffeine routine on day of testing 
 Have a light lunch and try to eat similar-sized meal across two sessions 
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Appendix F: Experimental questionnaire and extended screening 
 
Date ____/____/____      Participant ID _____________ 
 
1.        What grade of school did you complete (up to year 12/secondary school)? 
            Year_______ 
 
2.        Have you completed any courses after school? 
            No…………………………….…0 
            Yes, trade/technical…...1 
            Yes, university………….…2 
            Specify qualifications___________________________ 
 
3.        Are you currently studying? 
            No…………………………………0 
            Yes, trade/technical……….1 
            Yes, university……….…….. 2 
            Specify ___________________________ 
 
4.  How are you currently employed? Mark ONE response 
 Not employed ………..………….…1 
 Full time ………..……………………..2 
 Part time/casual ………..…………3 
 Full time student ………..…………4 
 Home duties ………..……………….5 
 Work and study …………………… 6 
 Part-time student ………..………..8 
 Other ………..…………………………..9 
 Specify________________________________ 
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Experimental session questionnaire 
Date ____/____/____     Participant ID _____________ 
 
1. Check that participant has abstained from alcohol for 24 hours and illicit drug use 
since completing the screening questionnaire 
2. Weight ___________ kg 
Height____________ cm 
BMI _____________ 
 
3.  Have you consumed any medications in the past week (or any prescribed 
medications since completing the screening questionnaire)? 
If yes, please detail:  
 
 
3. How many cups of coffee (or any other caffeinated drinks/products) have you 
consumed today? _____  
If > 0. How many hours since your last caffeinated drink ______ hours 
4. Have you had any tobacco or nicotine products today? Yes / No  
If yes, how many cigarettes (or nicotine products) have you had today? ____ 
If yes, How many hours since your last cigarette (nicotine product) ______ hours 
5.  What have you had to eat today? How long since you last ate something?___mins 
__________________________________________________________________________ 
__________________________________________________________________________ 
__________________________________________________________________________ 
__________________________________________________________________________ 
6. Approximately how many hours sleep did you have last night? ____ 
 
Medication Number of 
occasions 
Time since last used Estimated dose 
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These questions are related to how you have been feeling over the last 4 weeks. Remember, any 
information you provide is completely confidential. 
Please circle the most appropriate response.  
In the last 4 weeks, about how often – 
 
 
Total= 
(≥30) 
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SPQ 
Please answer each item by checking Y (Yes) or N (No). Answer all items even if unsure of 
your answer. When you have finished, check over each one to make sure you have answered 
them. 
1. People sometimes find me aloof and distant Yes        No   
2.  Have you ever had the sense that some person or force is around 
you, even though you cannot see anyone? 
Yes        No   
3. People sometimes comment on my unusual mannerisms and habits Yes        No   
4. Are you sometimes sure that other people can tell what you are 
thinking? 
Yes        No   
5. Have you ever noticed a common event or object that seemed to be a 
special sign for you? 
Yes        No   
6. Some people think that I am a very bizarre person Yes        No   
7. I feel I have to be on my guard with friends Yes        No   
8.  Some people find me a bit vague and elusive during a conversation Yes        No   
9. Do you often pick up hidden threats or put downs from what people 
say or do? 
Yes        No   
10. When shopping do you get the feeling that other people are taking 
notice of you? 
Yes        No   
11. I feel very uncomfortable in social situations involving unfamiliar 
people 
Yes        No   
12.  Have you had experiences with astrology, seeing the future, UFos, ESP, 
or a sixth sense? 
Yes        No   
13. I sometimes use words in unusual ways 
 
Yes        No   
14. Have you found that it is best not to let other people know too much 
about you? 
Yes        No   
15. I tend to keep in the background on social occasions 
 
Yes        No   
16.  Do you ever suddenly feel distracted by distant sounds that you are 
not normally aware of? 
Yes        No   
17. Do you often have to keep an eye out to stop people from taking 
advantage of you? 
 
Yes        No   
18.  Do you feel that you are unable to get ‘close’ to people? 
 
Yes        No   
19. I am an odd, unusual person 
 
Yes        No   
20.  I find it hard to communicate clearly what I want to say to people 
 
Yes        No   
21. I feel very uneasy talking to people I do not know well 
 
Yes        No   
22. I tend to keep my feeling  to myself 
 
Yes        No   
 83 
Total=(≥17)  
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Participant Code:             
 Test Point: 
PROFILE OF MOOD STATES-SHORT FORM 
Below is a list of words that describe feelings people have. Please read each one 
carefully. Then circle ONE answer to the right, which best describes how you are feeling 
AT THE MOMENT. 
The numbers refer to these phrases: 
0=not at all 
1=a little 
2=moderately 
3=quite a bit 
4= extremely 
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Appendix H: Karolinska Sleepiness Scale 
*DELETED IN CASE OF COPYRIGHT* 
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Appendix I: Visual analogue scale subjective performance 
PRE TEST    Participant number:   Test point:  
 
Visual Analogue Scales of Subjective Performance 
Please mark on each line at the point which most accurately reflects your 
level of agreeness AT THE MOMENT with the below statement: 
 
1. I feel alert 
STRONGLY  
AGREE 
 STRONGLY  
DISAGREE 
2. I feel that I will be able to perform the attentional tasks to the best of my ability 
STRONGLY 
 AGREE 
 STRONGLY  
DISAGREE 
3.I do not feel that my driving would be impaired right now 
STRONGLY  
AGREE 
 STRONGLY 
DISAGREE 
4.I feel capable of driving safely right now 
STRONGLY  
AGREE 
 STRONGLY 
DISAGREE 
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Appendix J: Visual analogue scale drug effects 
 
Participant number:   Test point:  
 
Visual Analogue Scales of Subjective Drug Effects 
Please mark on each line at the point which most accurately reflects your 
level of agreeness AT THE MOMENT with the below statement: 
 
 
1. Strength of drug effect 
NO EFFECT 
 
 VERY 
STRONG 
EFFECT 
2. Liking of the drug effect 
DISLIKE VERY 
MUCH 
 
 LIKE VERY 
MUCH 
3. Alert level 
NOT ALERT 
 
 VERY ALERT 
4. Intoxication 
NOT 
INTOXICATED 
 
 VERY 
INTOXICATED 
 
 
From 0-100%, how certain are you that you received modafinil today? 
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Appendix K: Side effects checklist 
During this experimental session have you experienced any of the 
following symptoms? 
Yes      No  
        headache 
        nausea 
        dry mouth 
        runny nose 
        sore throat 
        nervous feeling 
        dizziness 
  
 
Are you currently experiencing any other adverse symptoms? Please 
specify. 
 
 
  
 89 
Appendix L  
Table 6 
Group Means for Fatigue and Mood by Drug Condition at Post-Ingestion 
 
 Modafinil Placebo p  g 
POMS-SF subscales     
Tension-Anxiety 3.72 (5.07) 2.00 (2.95) .062 0.41 
Depression-Dejection 0 (0) 1.28 (3.27) .116 -0.54 
Anger-Hostility 0.06 (0.24) 0.28 (0.96) .215 -0.31 
Vigour-Activity 9.83 (6.21) 4.44 (3.62) .002 1.04 
Fatigue-Inertia 4.28 (3.37) 6.44 (4.63) .067 -0.52 
Confusion-
Bewilderment 
1.83 (2.92) 2.33 (3.12) .095 -0.16 
Note… 
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Appendix M 
Table 12 
Main Effects and Interactions for Accuracy 
Factor F df p η2p 
Time 0.01 1, 17 .937 .000 
Drug 0.25 1, 17 .624 .014 
Cue 18.92 1.7, 29.4 .001 .527 
Congruency 52.21 1, 17 .001 .754 
Time x Drug 1.71 1, 17 .208 .091 
Time x Cue 2.54 1.71, 29.06 .103 .130 
Time x Congruency 11.69 1, 17 .003 .407 
Drug x Cue 0.43 1.9, 31.6 .641 .025 
Drug x Congruency 0.00 1, 17 .982 <.001 
Cue x Congruency  12.09 1.9, 31.9 <.001 .416 
Time x Drug x Cue 1.64 1.5, 26.0 .215 .088 
Time x Drug x Congruency 2.17 1, 17 .159 .113 
Time x Cue x Congruency 1.46 27.3, 319.1 .249 .079 
Drug x Cue x Congruency 0.92 1.9, 33.0 .410 .051 
Time x Drug x Cue x 
Congruency  
0.15 1.7, 29.4 .834 .009 
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Appendix N 
Table 14 
Main Effects and Interactions of Site, Drug, Cue and Congruency for Peak N1 
Amplitude 
Factor/s F df p η2p 
Site 2.75 1, 17 .115 .139 
Drug 3.06 1, 17 .098 .153 
Cue 64.25 1.5, 25.7 <.001 .791 
Congruency 0.44 1, 17 .516 .025 
Drug x Site 0.04 1, 17 .844 .002 
Cue x Site 2.26 1.4, 23.5 .139 .117 
Congruency x Site 0.03 1, 17 .876 .001 
Drug x Cue 0.14 1.6, 27.7 .833 .008 
Drug x Congruency 0.13 1, 17 .728 .007 
Cue x Congruency  1.69 1.7, 29.3 .205 .090 
Drug x Cue x Site 0.80 1.9, 31.8 .450 .045 
Drug x Congruency x Site 1.06 1, 17 .318 .059 
Cue x Congruency x Site 0.03 1.6, 27.3 .947 .002 
Drug x Cue x Congruency 0.07 1.9, 33.0 .932 .004 
Drug x Cue x Congruency x Site 2.61 1.7, 29.4 .093 .133 
 
